Hydroxychloroquine Postexposure Prophylaxis for COVID-19 Fails

Save

NEJM has reported that the use of hydroxychloroquine did not prevent symptomatic COVID-19 infection when used within 4 days after SARS-CoV-2 exposure.

Currently for persons who are COVID exposed, the standard of care is quarantine and there is no known preventative therapy.

First Look at COVID-19 Global Rheumatology Alliance Registry

Save

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect on outcomes and c) steroid increase and TNF inhibitor decrease the odds of hospitalization.

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

TNR Grand Rounds - Cytokine Storm Syndromes

Save

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The program was moderated by Dr. Jack Cush.

Hydroxychloroquine Improves Survival in Lupus

Save

Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients. Yet, a recent report reaffirms what rheumatologists have known for years - that HCQ use is associated with better outcomes in systemic lupus erythematosus, including survival.  

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

Save

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

TNR - COVID-Rheumatology Registry & COVID in OZ

Save

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID in Australia and pragmatic COVID management.

Systemic Sclerosis Future Therapies and Outcome Measures

Save

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder.

RheumNow Podcast - COVID Kids and Men (5.15.20)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

CDC on Pediatric Multi-System Inflammatory Syndrome

Save

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

RheumNow Podcast – The Beat Goes On (5.8.20)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

COVID-19 and Thrombotic Complications

Save

Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection.

Physical Activity Prevents Hospitalization

Save

Modifiable lifestyle choices can impact long term health.  A recent study shows that usual and increased physical activity can results in less hospitalization amongst the the general population.

#EULAR2020 ABST#OP0015Plenary session: very low serum urate < 4 mg/dL in men assc w/increased CV mortality; 40,000 pt study. NOTE: this may be driven by poorly controlled diabetes as hyperglycemia has a uricosuric effect; from NHANES database @MassGeneralNews @RheumNow https://t.co/jnhkS436JZ